Lung Cancer
Lung cancer is a heterogenous disease compromising of several subtypes including non-small cell lung carcinoma (NSCLC), adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Recent advances in molecular techniques has enabled the identification of molecular abnormalities leading to emergence of personalized treatment strategies.
Mutations, gene rearrangements, amplification and deletion are the main molecular alteration seen in lung cancer.
Key NSCLC biomarkers
Key Adenocarcinoma biomarkers
Key Squamous Cell Carcinoma biomarkers
Lung cancer tissue controls
In addition to other tools, OriGene has the largest collection Mutant ORF Clones, Ultra specific antibodies (UltraMAB), CytoSections (Control for IHC, ICC) and other tools for genes associated with lung cancer.
References:
- Villalobos et al, 2017 Feb; 31(1): 13–29. doi: 10.1016/j.hoc.2016.08.006
- Pakkala et al., 2018 Aug 9;3(15):e120858. doi:10.1172/jci.insight.120858
- Goebel et al.; 2020 July 1 11 (7): doi:10.1039/d0md00096e
- Ryan et al., 2018 Nov 15 (11): doi:10.1038/s41571-018-0105-0
- Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017 Jan 19;18(1):197. doi:10.3390/ijms18010197 PMID: 28106826; PMCID: PMC5297828.https://pubmed.ncbi.nlm.nih.gov/28106826/.